Abstract:Objective: The low expression of somatostatin receptor (SSTR) subtypes in somatotropinoma is associated with a poor response to somatostatin analogs (SSAs). However, the correlation between SSTRs and tumor invasion has not yet been clarified. Therefore, the authors aimed to investigate the relationship between SSTRs and tumor invasion, as well as the correlation between tumor invasiveness and pharmacological response to SSAs. Methods: A total of 102 patients with acromegaly who underwent surgery between December 2016 and December 2021 at the largest pituitary tumor surgery center in southern China were included in this retrospective study. Patients were divided into the noninvasive tumor group (Knosp grades 0-2 and Hardy-Wilson grade I or II) and invasive group (either Knosp grade 3 or 4 or Hardy-Wilson grade III or IV). The positive response to SSAs was defined by the following criteria after at least 3 months of SSA treatment: 1) ≥ 50% reduction or age- and sex-adjusted normal range of insulin-like growth factor-1 (IGF-1) level; 2) ≥ 80% reduction in or normal range of growth hormone (GH) level; or 3) > 20% reduction in tumor volume. The reference for the normal range of age- and sex-adjusted serum IGF-1 levels was derived from a survey of 2791 healthy adults (1339 males and 1452 females) in China. Demographics and clinical characteristics including tumor size, biochemical assessment, expression levels of SSTRs, and response to preoperative SSAs were compared between the invasive group and noninvasive group. Receiver operating characteristic (ROC) curve analysis was performed to assess the association between SSTR2 and tumor invasion. Results: Compared with the noninvasive group, the invasive group presented with a larger tumor size (9.99 ± 10.41 cm3 vs 3.50 ± 4.02 cm3, p < 0.001), relatively lower SSTR2 expression (p < 0.001), and poorer response to SSAs (36.4% vs 91.7%, p < 0.001). In addition, there was a significant negative correlation between SSTR2 mRNA level and tumor size (r = -0.214, p = 0.031). However, there were no statistically significant differences in the expression of SSTR1, SSTR3, and SSTR5 between the groups. ROC analysis revealed that the low SSTR2 mRNA level was closely associated with tumor invasion (area under the curve 0.805, p < 0.0001). Conclusions: Tumor invasion is negatively correlated with SSTR2 level but is not associated with other SSTR subtypes. Patients with invasive tumors have a poorer response to SSA therapy, which may be due to the low level of SSTR2 expression. Therefore, SSTR2 could be considered as a routine investigative marker for aiding management of postoperative residual tumors.

Genetic abnormalities of somatostatin receptors in pituitary tumors

Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas

Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: A pathologist's perspective

Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant

Expression of Somatostatin Receptor 2 in Somatotropinoma Correlated with the Short-Term Efficacy of Somatostatin Analogues

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System.

Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology

Expression of Somatostatin Receptors in Human Pancreatic Tumor

Correlation between tumor invasion and somatostatin receptor subtypes in acromegaly

Expression of Somatostatin Receptor Subtype 2 in Growth Hormone-Secreting Pituitary Adenoma and the Regulation of Mir-185

Somatostatin receptors and the associated intracellular machinery: the two sides of the coin

A novel somatostatin receptor ligand for human ACTH - and GH -secreting pituitary adenomas

Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias

Clinicopathological analysis of densely and sparsely granulated somatotroph tumors of pituitary

Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro

Efficacy and Predictors of Short-Term First-Generation Somatostatin Analog Presurgical Treatment in Acromegaly: A Hospital-Based Study of 237 Cases.

Connexin 36 Mediated Intercellular Endoplasmic Reticulum Stress Transmission Induces SSTA Resistance in Growth Hormone Pituitary Adenoma

Somatostatin receptors: from signaling to clinical practice

Presurgical Treatment with Somatostatin Analogues in Growth Hormone-Secreting Pituitary Adenomas: A Long-Term Single-Center Experience

REGULATION OF SOMATOSTATIN RECEPTOR MESSENGER-RNA EXPRESSION

Somatostatin Receptor Based Imaging and Radionuclide Therapy